These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37662490)

  • 21. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of COPD patients treated with single‑inhaler triple therapy in real-life clinical practice.
    Lassan S; Keszegh J; Lassanova M
    Bratisl Lek Listy; 2022; 123(1):27-36. PubMed ID: 34967655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modified Delphi consensus study to identify improvement proposals for COPD management amongst clinicians and administrators in Spain.
    Arriero-Marín JM; Orozco-Beltrán D; Carratalá-Munuera C; López-Pineda A; Gil-Guillen VF; Soler-Cataluña JJ; Chiner-Vives E; Nouni García R; Quesada JA
    Int J Clin Pract; 2021 May; 75(5):e13934. PubMed ID: 33675283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care.
    Alcázar Navarrete B; Ancochea Bermúdez J; García-Río F; Izquierdo Alonso JL; Miravitlles M; Rodríguez González-Moro JM; Soler-Cataluña JJ
    Arch Bronconeumol (Engl Ed); 2019 Sep; 55(9):478-487. PubMed ID: 30967279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
    Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
    Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
    Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical burden of illness among patients with severe eosinophilic COPD.
    Müllerová H; Meeraus WH; Galkin DV; Albers FC; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():741-755. PubMed ID: 31114180
    [No Abstract]   [Full Text] [Related]  

  • 29. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Long H; Xu H; Janssens JP; Guo Y
    Respir Res; 2021 Jul; 22(1):209. PubMed ID: 34301267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
    Kendall R; Martin AA; Shah D; Shukla S; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1815-1825. PubMed ID: 37636901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice.
    Sansbury LB; Bains C; Lipson DA; Ismaila AS; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1255-1264. PubMed ID: 33986594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Wu B; Mannino D; Mu G; Stiegler M; Bogart M
    Pulm Ther; 2022 Jun; 8(2):195-208. PubMed ID: 35467260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus.
    Ramakrishnan S; Janssens W; Burgel PR; Contoli M; Franssen FME; Greening NJ; Greulich T; Gyselinck I; Halner A; Huerta A; Morgan RL; Quint JK; Vanfleteren LEGW; Vermeersch K; Watz H; Bafadhel M
    Int J Chron Obstruct Pulmon Dis; 2021; 16():321-332. PubMed ID: 33623379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus.
    Miravitlles M; Soler-Cataluña JJ; Alcázar B; Viejo JL; García-Río F
    Pulm Pharmacol Ther; 2018 Feb; 48():97-103. PubMed ID: 29031616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
    Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-management behaviors to reduce exacerbation impact in COPD patients: a Delphi study.
    Korpershoek YJ; Bruins Slot JC; Effing TW; Schuurmans MJ; Trappenburg JC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2735-2746. PubMed ID: 28979116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.